SA
VRCA icon

Sovran Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Sovran Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,658
Closed -$249K – 611
2025
Q4 		$249K Sell
32,658
-41,147
-56% -$228K 0.02% 485
2025
Q3 		$261K Sell
73,805
-1,234
-2% -$7.44K 0.02% 457
2025
Q2 		$646K Buy
75,039
+35,823
+91% +$193K 0.07% 268
2025
Q1 		$192K Sell
39,216
-1,489
-4% -$9.63K 0.02% 451
2024
Q4 		$267K Buy
+40,705
New +$447K 0.04% 359

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sovran Advisors's VRCA Position: Q1 2026 in Review

Sovran Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 32,658 shares — an estimated $249K sold.

Sovran Advisors first reported a position in VRCA in Q4 2024 and held it in 5 quarters. The position peaked at $646K in Q2 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Sovran Advisors reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sovran Advisors sold 32,658 Verrica Pharmaceuticals shares in Q1 2026, an estimated $249K.
  • Sovran Advisors first reported a position in Verrica Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Sovran Advisors's Verrica Pharmaceuticals position peaked at $646K in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Sovran Advisors's 13F filing for Q1 2026, filed 1 May 2026.